Rgenix is a preclinical stage biotechnology company with a mission to develop first-in-class cancer drugs designed specifically to target, both primary tumors and metastasis, the main cause of mortality in cancer patients. Founded on the ground-breaking research of Dr. Sohail Tavazoie of Rockefeller University, Rgenix has developed a novel target discovery platform and is leading the revolution in next-generation cancer therapies with four separate oncology programs to treat highly aggressive cancer subtypes, including melanoma (small molecule), colorectal cancer (small molecule), and triple-negative breast cancer (small molecule and monoclonal antibodies).
Dr. Sohail Tavazoie and Dr. Saeed Tavazoie publish new findings on breast cancer metastasis, in Nature
Dr. Sohail Tavazoie’s Lab publishes on a novel mechanism to combat melanoma, in Cell
Dr. Sohail Tavazoie’s Lab publishes on a miRNA network underlying melanoma metastasis, in Cell
In cancer, molecular signals that recruit blood vessels also trigger metastasis